Search results for: "artificial intelligence"

By taking a look at Akerlund v. Atlas Air, Inc., 2026 WL 1993146 (11th Cir. July 10, 2026), that makes this the third straight week in which we are pleased with a sensible vaccine decision. In this published case, the Eleventh Circuit affirms that an airline’s COVID-19 vaccination mandate did not subject its employees who…

Bexis recently attended the Spring Conference of the Product Liability Advisory Council (“PLAC”).  PLAC meetings are usually good for new blogpost ideas, and this one was no exception.  Today’s idea comes from an unusual source, though – the final day’s ethics presentation.  That presentation was about artificial intelligence, mostly in the mass tort context.  One…

Today’s guest post is another tech-related discussion from Reed Smith‘s Jamie Lanphear. Given the increasing ubiquity of artificial intelligence (“AI”) in legal practice, the notion of AI prompts and output becoming yet another front in the never-ending ediscovery wars is concerning. Here are Jamie’s latest thoughts on the latest pertinent caselaw in this…

We typed the following question into a simple AI prompt:  “What is the difference between admonish and deter?”  The response started with “The primary difference between admonish and deter lies in their intent and timing:  admonishing is form of active, often verbal correction or warning regarding past or present behavior, while deterring is an act…

Today’s guest post is by Reed Smith‘s Jamie Lanphear. She has long been interested in tech issues, and particularly in how they might intersect with product liability. This post examines product liability implications of using artificial intelligence (“AI”) for medical purposes. It’s a fascinating subject, and as always our guest posters deserve 100%…

We’ve become aware that some clients are using artificial intelligence (AI) to summarize or analyze things like complaints, briefs, internal documents, or even – horror of horrors! – law firm bills.  If the client performing these tasks is an in-house lawyer, such work might be protected by the attorney client privilege or work product doctrine…

Drug & Device Resources

Bexis’ Book

FDA-regulated products now account for an estimated one-fifth of overall economic activity in the U.S. They have also been the focus of a litigation explosion. This timely guide covers all aspects of litigation involving drugs, medical devices, vaccines and other FDA-regulated prescription products.
Learn more about this book